Close Menu

GeneCentric Diagnostics

The firm is developing a biomarker panel to detect mutations in mesenchymal cells, with the goal of guiding drug treatment and improving earlier patient intervention.

The partners will evaluate patients' responses to immunotherapeutic drugs, including PD-1 and PDL-1 inhibitors, based on bladder cancer subtypes.

The University of North Carolina at Chapel Hill's technology is based on set of patient-cell derived gene signatures for classifying four pancreatic subtypes.

The firm has developed a new classifier for bladder cancer and continues to work with pharma companies in the lung cancer space.

BMS has provided funding to the diagnostic company to support build-out of its new lab and development of its platform, which they hope can identify new biomarkers for Opdivo.

Science reports that a new White House Office of Management and Budget memo rescinds previous ones that helped research institutions deal with pandemic-related closures.

Researchers report on a concerning strain of the H1N1 swine flu virus found among pigs in China, Agence France Presse reports.

The Associated Press reports that US officials are considering allowing pooled COVID-19 testing.

In Genome Research this week: Y chromosome gene expression analysis, de novo mutations rise with paternal age in rhesus macaques, and more.